KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Capital Employed (2016 - 2025)

Alnylam Pharmaceuticals' Return on Capital Employed history spans 15 years, with the latest figure at 0.15% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 20.0% year-over-year to 0.15%; the TTM value through Dec 2025 reached 0.15%, up 20.0%, while the annual FY2025 figure was 0.16%, 22.0% up from the prior year.
  • Return on Capital Employed reached 0.15% in Q4 2025 per ALNY's latest filing, up from 0.08% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.15% in Q4 2025 to a low of 0.32% in Q2 2023.
  • Average Return on Capital Employed over 5 years is 0.15%, with a median of 0.18% recorded in 2022.
  • Peak YoY movement for Return on Capital Employed: surged 35bps in 2024, then fell -9bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.25% in 2021, then fell by -14bps to 0.28% in 2022, then soared by 65bps to 0.1% in 2023, then skyrocketed by 41bps to 0.06% in 2024, then surged by 350bps to 0.15% in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Return on Capital Employed are 0.15% (Q4 2025), 0.08% (Q3 2025), and 0.06% (Q2 2025).